Exploring New and Promising Genetic Biomarkers for Evaluating Traumatic Brain Injuries: A Case-Control Study
2025

New Genetic Biomarkers for Traumatic Brain Injuries

Sample size: 40 publication 10 minutes Evidence: moderate

Author Information

Author(s): Rabou Yasmin Kamal Abd, Zayed Abeer Ahmed, Fahim Sally A., Abdelgwad Marwa, Fiki Ahmed El, Fayed Nermin Nabil

Primary Institution: Cairo University

Hypothesis

Can specific blood-based biomarkers improve the diagnosis and prognosis of traumatic brain injuries?

Conclusion

AKT3, hsa-miR-16-5p, and GSK-3β are effective diagnostic biomarkers for traumatic brain injury, while MALAT-1 is particularly useful for severe cases.

Supporting Evidence

  • AKT3 levels increased significantly in TBI patients compared to controls.
  • GSK-3β levels decreased over time in TBI patients.
  • hsa-miR-16-5p levels were higher in mTBI patients compared to modTBI and sTBI.
  • MALAT-1 showed significant increases in severe TBI cases.
  • ROC curve analysis indicated excellent diagnostic performance for AKT3, GSK-3β, and hsa-miR-16-5p.

Takeaway

Doctors can use certain blood tests to better understand brain injuries and how serious they are, helping patients get the right care.

Methodology

The study involved a case-control design with blood samples from 30 TBI patients and 10 healthy controls, analyzing specific biomarkers using RT-PCR.

Potential Biases

Potential bias due to the small sample size and the subjective nature of some assessments.

Limitations

The small sample size limited the generalizability of the findings.

Participant Demographics

Participants included 30 TBI patients aged 18-45, with a balanced gender distribution, and 10 healthy controls matched for age and sex.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s11064-024-04292-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication